Pipeline | SN | Product Number | Product Introduction |
---|---|---|---|
Oncology | 1 |
JMX-2002
|
Class 2.2 innovative liposomes are intended for conventional chemotherapy of multiple tumors, including non-small cell lung cancer, and can significantly reduce the toxicity issues caused by chemotherapy drugs. |
2 |
JM045
|
2.2 class long-acting microspheres for chemical drugs, used for endocrine therapy of sex hormone related tumors | |
3 |
JMX-2006
|
2.2 class long-acting microspheres for chemical drugs, used for endocrine therapy of sex hormone related tumors | |
Cardiovascular Diseases | 4 |
JMX-2005
|
Class 2.2 innovative liposomes for chemical drugs, used in vascular diseases to meet clinical needs |
Respiratory Diseases | 5 |
JMX-2007
|
2.2+2.4 inhalation formulations of chemical drugs, with no competition in the same variety both domestically and internationally |
6 |
JMX-2101
|
Class 2.2 inhalation preparations for chemical drugs, with high medication convenience | |
7 |
JMZ-2201
|
Improved traditional Chinese medicine, inhalation dosage form, good safety, convenient for children's treatment | |
8 |
JMX-2201
|
Tripartite inhaled aerosols are expected to become iterative treatment products | |
Pain | 9 |
JM023
|
2.2 class long-acting microspheres for chemical drugs, meeting the clinical pain treatment needs |
10 |
JMX-2102
|
Class 2.2 long-acting microsphere compound formulation for chemical medicine, meeting the clinical pain treatment needs |
Compound liposome technology
Weak base/acid drug liposome system
Modified targeted liposomes
Liposome-device integration and o🌼ther technologies
Dry powder inhalers
Metered dose inhaler
Nasal spray
Other mucosal drug delivery formulations
Single emulsion platform
Complex emulsion platform
Phase separation platform
Suspension technology
Long-acting gels
Focused TCM development: categories 1.1 and 1.2
Expanded TCM pipelines: nephropathy, respiratory diseases, pain, and cardiovascular diseases
Developing next-generation TCM products: identification of active components, development of novel TCM entities, IND filing, clinical developemnt, NDA filing
Advancing TCM series: reꦇproduction of traditional products, optimization of process development, improvement of quality, exploration of clinical value
API manufacturing (formulation platforms / API registration): liposomes, inhalation formulations, microspheres, solid dosage forms, liquid dosage forms
Developing novel chemical technologies and green processes: chiral syntheses and telescoping syntheses, high performance membrane and resin separation, impurities separation and syntheses, quality control, polymorph study
Product supporting: 🤪marketed and license-ౠin products of Jemincare Group
Immediate release formulations (rapid onset of action)
Solubility-improving technologies for insoluble molecules
Sustained release formulations (daily administration)
Multi-unit formulation for extended and controlled rele💧ase
High-end oral liquid preparations: oral emulsion, oral suspension, oral phospholipid dispersion, and enteral nutrition emulsion
Special injectables: lipid injectable emulsions, ꦓplasma substitut♋e, injectable suspension